Clinical Trial Update: Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine For The First Line Treatment of Pancreas Cancer [Phase 2]

View source ↗

Summary

This document notes a completed Phase 2 trial comparing nab-paclitaxel plus gemcitabine versus gemcitabine alone as first-line therapy for pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Hacettepe University | Conditions: Pancreatic Neoplasm | Phase 2 | Status: COMPLETED